Quantcast
Home » News » Justice
Home » News » Justice

Spanish priest dies of Ebola; U.N. debates ethics

First Published Aug 12 2014 08:56AM      Last Updated Aug 12 2014 08:56 am

Madrid • A Spanish missionary priest being treated for Ebola died Tuesday in a Madrid hospital amid a worldwide debate over who should get experimental Ebola treatments.

After holding a teleconference with medical experts around the world, the World Health Organization declared it is ethical to use unproven Ebola drugs and vaccines in the current outbreak in West Africa provided the right conditions are met. Its statement, however, sidestepped the key question of how to decide who should get the limited drugs.

Two more experimental Ebola treatments were reportedly heading Tuesday to Liberia to be used on two infected doctors — the first Africans to receive the untested drug.



The U.N. health agency says 1,013 people have died so far in the Ebola outbreak in West Africa and authorities have recorded 1,848 suspected or confirmed cases. The killer virus, spread by direct contact with bodily fluids like blood, diarrhea and vomit, was detected in Guinea in March and has since spread to Sierra Leone, Liberia and possibly Nigeria.

Two Americans and reportedly the Spanish priest who died had gotten the drug named ZMapp, which has never been tested in humans. But the vast majority of Ebola victims have been Africans, and some have protested that their citizens are not getting access to the novel drugs.

"We can’t afford to be passive while many more die," said Aisha Dab, a Senegalese-Gambian journalist who was tweeting using the hashtag "GiveUsTheSerum."

The company that makes ZMapp said Monday that its available supply was "exhausted."

The Spanish missionary, 75-year-old Miguel Parajes, died in Madrid’s Carlos III Hospital, the hospital and his order said. The hospital would not confirm that he had been treated with the drug, but his order and Spain’s Health Ministry said earlier that he would be. His body will be cremated Wednesday to avoid any further public health risks, the hospital said.

Parajes had worked for the San Juan de Dios hospital order, a Catholic aid group, and had been helping to treat people with Ebola in Liberia when he became ill and was evacuated.

WHO decided it is ethical to use experimental treatments and vaccines in West Africa even though there’s no evidence yet that these experimental drugs can actually help fight Ebola and it is possible they could be harmful or have no effect at all.

The agency said the size of the outbreak — the biggest-ever in history— made the experimental use of drugs ethical.

"It seems some of the usual methods we’re using ... are not working as well," said Dr. Marie-Paule Kieny, an assistant director-general at WHO, during a press conference. "We don’t have enough people to rely on the traditional methods if we want to stop the outbreak as soon as possible."

WHO said it was OK to use unproven treatments if certain criteria were met, including informed consent, confidentiality and freedom of choice.

The panel said a "more detailed analysis and discussion" are needed to decide who should have access to any experimental treatments, since there is an extremely limited supply of the novel drugs and vaccines. WHO also said the world had "a moral duty" to collect evidence about any untested treatment’s safety and effectiveness in proper scientific trials.

Kieny said it was difficult to judge how the few experimental treatments have been doled out so far.

"I don’t think there could be any fair distribution of something available in such small quantities," she said.

She added that some companies were speeding up trials of their new Ebola vaccines and it was possible there might be some preliminary safety data by the end of the year.

West African nations are struggling to control both the deadly outbreak and the fear it has engendered. Most airlines flying in and out of the Liberian capital of Monrovia have suspended flights amid the unprecedented health crisis.

 

 

» Next page... 2 Single page

 

 

comments powered by Disqus